These medications for BPH have known risks and may have new side effects.
March 2026 in “The Aging Male” PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
November 2017 in “Reactions Weekly” Testosterone undecanoate caused hair loss; finasteride improved it but caused stomach issues for one patient.
13 citations
,
December 2017 in “Archives of Medical Sciences” Rivaroxaban can cause liver injury, allergic reactions, blood vessel inflammation, and hair loss, but these side effects are rare.
7 citations
,
January 2004 in “Drugs of today” 5alpha-reductase inhibitors help treat hair loss and prostate issues but may cause sexual side effects.
6 citations
,
December 1996 in “The Journal of Clinical Pharmacology” Terazosin and finasteride together cause no major issues.
39 citations
,
May 2011 in “Movement Disorders” Finasteride may help reduce symptoms in male Tourette syndrome patients.
2 citations
,
August 2024 in “Heliyon” Metformin may help mild COVID-19 cases, while Oseltamivir, Tamoxifen, and Dexamethasone are suggested for severe cases.
46 citations
,
September 2016 in “Clinical, Cosmetic and Investigational Dermatology” Hormonal treatments are effective for severe or persistent acne and should be used with other acne therapies, considering potential side effects.
July 2018 in “Reactions Weekly” Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
November 2021 in “Evidencia” Young patients using finasteride may have higher risks of anxiety, depression, and suicidal thoughts.
2 citations
,
August 2016 in “British Journal of Clinical Pharmacology” The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.
13 citations
,
April 2019 in “Seizure” Valproic acid increases the risk of hair loss more than other drugs, especially in migraine patients, and lamotrigine may be a safer alternative.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
April 2010 in “Nature Reviews Urology” 
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
53 citations
,
October 1993 in “Drug Safety” Oral retinoids can cause side effects ranging from mild to severe, including birth defects, and require careful monitoring and contraception.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
January 2015 in “Current Opinion in Endocrinology, Diabetes and Obesity” Finasteride may help reduce COVID-19 infection by altering a key gene.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
5 citations
,
July 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.
1 citations
,
January 2018 in “Journal of Neurology Research” A young man had rare serious side effects from an epilepsy drug, leading to stopping the drug.
4 citations
,
February 2013 in “Revista De Saude Publica” Pill organizers and cutters can help with taking medication regularly but may affect the medication's effectiveness and safety.
January 1993 in “Journal of International Medical Research” The document corrects errors in previous articles, including a reversed term, updated subject weights, hair count data, and reference numbering.
5-ARI therapy may help prevent prostate cancer progression.
May 2026 in “Frontiers in Pharmacology” This study investigated the impact of long-term 5α-reductase inhibitor (5-ARI) use on survival in men with renal cell carcinoma (RCC) using data from 31,927 men in Korea. The study found that long-term use of 5-ARIs, such as finasteride or dutasteride, was associated with significantly lower all-cause mortality, particularly in patients who did not undergo surgery or systemic therapy and had low comorbidity. The results suggest that androgen modulation through 5-ARIs may positively influence RCC progression, indicating potential for these inhibitors as adjunctive treatments in specific clinical scenarios.
November 2007 in “Neuro-chirurgie/Neurochirurgie” Cyproterone acetate is a safe treatment that causes mild feminizing effects and is more effective with added estrogens.